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HPLC-UVAbstract This paper describes the development and validation of a HPLC method for the quan-
titation of Emtricitabine, Tenofovir, and Efavirenz in pure form and pharmaceutical formulations.
The Zorbax SB CN, (250 · 4.6 mm, 5 lm) column was used. UV detection was performed at
260 nm. The mobile phase consisted of methanol (A) and buffer at pH 4.5(B) using the gradient:
0–10 min (90% B), 10–22 min (35% B), and 22–25 min (90% B). The ﬂow rate was 1.5 ml/min in
ambient temperature. The injection volume of sample was 20 ll. The method showed to be linear
(r2 > 0.999), precise (RSD < 0.76%), accurate (recovery of 100.09% for Emtricitabine, 99.88%
for Tenofovir and 100.04% for Efavirenz), speciﬁc and robust. Three batches of Emtricitabine,
Tenofovir, and Efavirenz tablets were assayed by the validated method. The Emtricitabine contents
in the tablet samples varied from 99.94 to 101.60%. The Tenofovir content in the tablet samples
varied from 99.13 to 101.81% while Efavirenz content varied from 100.01 to 101.67%.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Tenofovir Disoproxil Fumarate (TDF) is a fumaric acid salt of the
bisisopropoxycarbonyloxymethyl ester derivative of tenofovir.
Chemically it is described as 9-[(R)-2[[bis[[(isopropoxycarbon-
yl)oxy]methoxy]phosphinyl] methoxy]propyl] adenine fumarate(Budawari, 2001). Fig. 1a shows the nucleotide reverse transcrip-
tase inhibitor (NtRTI) used in combinationwith other antiretrovi-
rals for the treatment of HIV infection (Martindale, 2002).
Emtricitabine (FTC) is a nucleoside reverse transcriptase inhibitor
(NRTI). Chemically it is described as 5-ﬂuoro-1-(2R,5S)-[2-
(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine (Fig. 1b). FTC is
the () enantiomer of thio analog of cytidine which differs from
other cytidine analogs, in that it has ﬂuorine in the 5th position.
FTC is an antiviral agent used for the prevention of perinatal
HIV-1 reverse transcriptase (Budawari, 2001). It is also active
against Hepatitis B virus (Martindale, 2002; Gish et al., 2005).
Efavirenz is a human immunodeﬁciency virus type-I (HIV-
I) speciﬁc non nucleoside reverse transcriptase inhibitor
(NNRTI). Efavirenz is chemically described as (S)-6-chloro-
4-(cyclopropylethynyl)-1, 4-dihydro-4-(triﬂuoromethyl)-2H-3,ne, Ten-
Figure 1 Chemical structure of (a) Tenofovir, (b) Emtricitabine and (c) Efavirenz.
2 A. Ramaswamy, A.S. Arul Gnana Dhas1-benzoxazin-2-one (Fig. 1c) Physician’s Desk Reference,
2008. A literature survey reveals that analytical methods based
on HPLC (Malipatil and Nandedkar, 2009; Sharma and Pooja
Gupta, 2009; Appala et al., 2008; Rolim-Neto, 2011;
Montgomery et al., 2001), HPTLC (Joshi et al., 2009;
Laxman et al., 2010), and UV spectrometry (Sockalingam
et al., 2005; Shirkhedkar Atul et al., 2009) are available for
the determination of these drugs individually and in combina-
tion with other drugs in different dosage forms. Some papers
have described the analysis of combination with other drugs
in plasma, based on HPLC (Kandagal et al., 2008; Deirdre
Fox et al., 2011; Rezk et al., 2005), stability indicating
(Sagar et al., 2009; Rao and Nikalje, 2009). However, there
is no method reported regarding the quantitation of Emtricit-
abine, Tenofovir and Efavirenz.
Hence, the aim of this study was to develop a simple,
precise, accurate, and validated HPLC method, using UV
detection to quantify Emtricitabine, Tenofovir, and Efavirenz
in pure form for pharmaceutical formulations. The molar
absorptivity of Emtricitabine, Tenofovir and Efavirenz in the
UV region was found to be at 260 nm. The validated method
was applied to the analysis of tablets containing Emtricitabine,
Tenofovir and Efavirenz (200 + 300 + 600 mg).2. Experimental
2.1. Reagents and materials
Emtricitabine, Tenofovir, and Efavirenz reference standards
were procured from Cipla Laboratories, Mumbai. Tablets were
purchased from local pharmacy which were manufactured by
Viraday, Cipla, Mumbai, India. Ultra-pure water was obtained
fromaMillipore system (Bedford,MA,USA).Methanol (HPLC
grade) was obtained from E-Merck (India) Ltd, Mumbai, India.
All other chemicals used in the analysis were of AR grade.Table 1 Retention factor (k) and Resolution (R) for Emtricitabine,
Emtricitabine Retention
factor (K)
Tenofovir Retention
factor (K)
Ef
fac
0.61 2.34 4
1.66 3.18 4
3.63 4.17 6
3.45 8.65 12
3.63 13.31 16
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The HPLC analyses were carried out on Waters 2695 separa-
tion module (Waters Corporation, USA) equipped with auto
sampler and Waters 2998 PDA detector, Zorbax SB CN,
(250 · 4.6 mm, 5 lm) column. UV detection was performed
at 260 nm. UV spectra scanning from 190 to 400 nm was
recorded online for peak identiﬁcation. The mobile phase
consisted of methanol (A) and buffer at pH 4.5(B). The best
separation was obtained between Emtricitabine, Tenofovir
and Efavirenz using the gradient: 0–10 min (90% B),
10–22 min (35% B), and 22–25 min (90% B). The ﬂow rate
was 1.5 ml/min. The injection volume of sample was 20 ll.
The separation of Emtricitabine, Tenofovir and Efavirenz
was evaluated in different proportions of these solvents and
for each condition, retention factor (k) and resolution (R) were
calculated and data are presented in Table 1.
2.3. Preparation of buffer (pH 4.5)
Two grams of ammonium acetate was weighed and dissolved
in 1000 ml of water. The pH of the solution was adjusted to
4.5 with orthophosphoric acid. The solution was ﬁltered
through 0.45 lm membrane ﬁlter.
2.4. Preparation of standard solution
About 100 mg of Emtricitabine, 150 mg of Tenofovir, and
300 mg of Efavirenz reference standards were accurately
weighed and transferred into a 100 ml volumetric ﬂask. 20 ml
of methanol was added to ensure complete solubilization and
the volume was adjusted with the mobile phase. Further
dilutions were made to get a ﬁnal concentration of 0.08 mg/ml
of Emtricitabine, 0.12 mg/ml of Tenofovir and 0.24 mg/ml of
Efavirenz.Tenofovir and Efavirenz.
avirenz Retention
tor (K)
Resolution(R) for
Tenofovir
Resolution(R) for
Efavirenz
.90 2.43 1.19
.93 11.25 4.11
.90 10.56 6.12
.43 17.41 7.47
.75 29.51 9.46
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Three different batches (A: X31006; B: X31079; C: X31025) of
tablets were analyzed using the validated method. For the
analysis, six replicates of each batch were assayed. The average
weight of the tablets was determined. Tablets were ﬁnely pow-
dered. A portion of the powder, equivalent to about 200 mg of
Emtricitabine, 300 mg of Tenofovir and 600 mg of Efavirenz
was accurately weighed and transferred into a 500 ml volumet-
ric ﬂask followed by the addition of 100 ml of methanol. The
solution was sonicated for 30 min and diluted with mobile
phase to volume. Further dilutions were made to get the ﬁnal
concentration equivalent to 0.08 mg/ml of Emtricitabine,
0.12 mg/ml of Tenofovir and 0.24 mg/ml of Efavirenz.
2.6. Validation (ICH Q2A, 1994; ICH Q2B, 1996)
2.6.1. Linearity
Standard stock solutions containing 1 mg/ml of Emtricitabine,
1.5 mg/ml of Tenofovir and 3 mg of Efavirenz were prepared,
in triplicate. Aliquots of these solutions were diluted with the
mobile phase to ﬁve different concentrations, corresponding
to 40–120 lg/ml of Emtricitabine, 80–160 lg/ml of Tenofovir
and 200–280 lg/ml of Efavirenz. Calibration curves for the
different concentrations versus peak area were plotted for
Emtricitabine, Tenofovir and Efavirenz and the obtained data
were subjected to regression analysis using the least squares
method with a weighting factor of 1/x.
2.6.2. Precision
The intra-day precision was evaluated by analyzing six sample
solutions (n = 6), at the ﬁnal concentration of analyses of
80 lg/ml of Emtricitabine, 120 lg/ml of Tenofovir and
240 lg/ml of Efavirenz. Similarly the inter-day precision was
evaluated in three consecutive days (n= 18). Emtricitabine,
Tenofovir, and Efavirenz concentrations were determined
and the relative standard deviations (RSD) were calculated.
2.6.3. Accuracy
Emtricitabine, Tenofovir, and Efavirenz reference standards
were accurately weighed and added to a commercial formula-
tion of tablet powder, at three different concentration levelsTable 2 Chromatographic parameters for Emtricitabine, Tenofovi
Zorbax SB CN,(250 · 4.6 mm, 5 lm) column.
Trial Mobile phase composition Injection volume Flow ml/m
1 Isocratic 20 ll 1
Acetonitrile:Buﬀer (30:70)
2 Isocratic 20 ll 1
Methanol:Buﬀer (40:60)
3 Isocratic 20 ll 1.2
Methanol:Buﬀer (30:70)
4 Gradient 20 ll 1.5
Acetonitrile:Buﬀer
5 Gradient 20 ll 1.5
Methanol:Buﬀer
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Efavirenz respectively). At each level, samples were prepared
in triplicate and the recovery percentage was determined.
2.6.4. Speciﬁcity
Spectral purities of Emtricitabine, Tenofovir, and Efavirenz
chromatographic peaks were evaluated using the UV spectra
recorded by a UV detector. In addition, a solution containing
a mixture of the tablet excipients was prepared using the
sample preparation procedure and injected onto the chromato-
graph, to evaluate possible interfering peaks.
2.6.5. Robustness
Six sample solutions were prepared and analyzed under the
established conditions and by variation of the following
analytical parameters: ﬂow rate of the mobile phase (1.35
and 1.65 ml/min), methanol and buffer as the mobile phase
(±2% of organic solvent) and mobile phase pH (4.3, 4.7).
Emtricitabine, Tenofovir, and Efavirenz contents were
determined for each condition and the obtained data were
submitted for statistical analysis.
2.6.6. Detection and quantitation limits
Limit of detection (LOD) (signal-to-noise ratio of 3) and limit
of quantiﬁcation (LOQ) (signal-to-noise ratio of 10) were mea-
sured based on the signal-to-noise ratio. Determination of the
signal-to-noise ratio is performed by comparing measured sig-
nal samples with known low concentration of analyte with
those of blank samples establishing the minimum concentra-
tion at which the analyte can be reliably detected and
quantiﬁed.
3. Results and discussion
The chromatographic parameters were initially evaluated
using a Zorbax SB CN (250 · 4.6 mm, 5 lm) column and a
mobile phase composed of methanol and buffer gradient.
The conditions for method development using the above said
column, with different proportions of mobile phase were
performed to obtain a good peak (Table 2). Under these
conditions the retention factors obtained for Emtricitabine,
Tenofovir and Efavirenz were 4.6, 14.3 and 17.7 and a shortr and Efavirenz at different mobile phase compositions using a
in pH (Buﬀer) Defect
3.5 Split peeks; less number of
theoretical plates were present
3.5 Split peeks
4 More retention time,
resolution was not satisfactory
4.5 Resolution was not
good and more tailing
4.5 Less retention time,
More theoretical plates, less tailing,
peek shape and resolution was found Good
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Figure 2 Schematic representation of chromatogram for Emtricitabine, Tenofovir and Efavirenz.
Table 3 Calibration curve data for Emtricitabine, Tenofovir and Efavirenz.
Regression parameters Emtricitabine Tenofovir Efavirenz
Regression coeﬃcient (r2) 0.999 0.999 0.999
Slope ± standard error 18275 ± 0.034 18754 ± 0.04 19719 ± 0.02
Intercept ± standard error (%) 1.03 ± 0.21 5.73 ± 0.01 37.56 ± 0.02
Concentration range(lg/ml) 40–120 80–160 200–280
Number of points 5 5 5
4 A. Ramaswamy, A.S. Arul Gnana Dhasrun rime (21 min), and so, this condition was adopted in sub-
sequent analysis (Fig. 2).
After the evaluation of Emtricitabine, Tenofovir, and
Efavirenz UV spectrum in the range of 200–400 nm, the
wavelength of 260 nm was selected for detection due to the
adequate molar absorptivity of Emtricitabine, Tenofovir, and
Efavirenz in this region and the higher selectivity of this wave-
length regarding possible interfering compounds or solvents in
the sample.
3.1. Validation
3.1.1. Linearity
A linear correlation was found between the peak areas and the
concentrations of Emtricitabine, Tenofovir and Efavirenz in
the assayed range. The regression analysis data are presented
in Table 3. The regression coefﬁcients (r2) obtained were higher
than 0.999 for both compounds (Fig. 3) which attest the
linearity of the method.
3.1.2. Analysis of ﬁxed dose combination tablets
Samples of ﬁxed dose combination of commercial tablets con-
taining 200 mg of Emtricitabine, 300 mg of Tenofovir and
600 mg of Efavirenz were analyzed using the validated method.
The results obtained are presented in Table 5. All the analyzed
batches presented Emtricitabine, Tenofovir and Efavirenz con-
tents very close to the labeled amount. The Emtricitabine con-
tent in the tablet samples varied from 99.77 to 101.53%. The
Tenofovir content in the tablet samples varied from 99.27 toPlease cite this article in press as: Ramaswamy, A., Arul Gnana Dhas, A.S. Developm
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101.67%.
3.1.3. Precision
Mean contents of Emtricitabine, Tenofovir, and Efavirenz in
the intra-day precision analysis (n = 6) were 80 lg/ml
(RSD= 0.76%), 120 lg/ml (RSD= 1.06%) and 240 lg/ml
(RSD= 0.68%) respectively. For the intra-day precision
n= 18 the mean contents obtained were 80 lg/ml (RSD =
0.77%), 120 lg/ml (RSD = 1.05%) and 240 lg/ml (RSD =
0.73%) for Emtricitabine, Tenofovir, and Efavirenz respec-
tively. RSD values lower than 2% assure the precision of the
method. The results obtained are presented in Table 4.
3.1.4. Accuracy
Accuracy was investigated by means of addition of Emtricita-
bine, Tenofovir, and Efavirenz reference standards to a mix-
ture of the tablet excipients. The mean recovery (n = 9) was
found to be 100.09%, (RSD= 0.51%), 99.88% (RSD=
0.30%) and 100.04% (RSD= 0.19%) for the drugs Emtricit-
abine, Tenofovir and Efavirenz respectively for demonstrating
the accuracy of the method. The results obtained are presented
in Table 6.
3.1.5. Speciﬁcity
Peak purities higher than 99.3% were obtained for Emtricita-
bine, Tenofovir and Efavirenz in the chromatograms of sample
solutions, demonstrating that other compounds did not
co-elute with the main peaks. The chromatogram obtainedent and validation of analytical method for quantitation of Emtricitabine, Ten-
oi.org/10.1016/j.arabjc.2014.08.007
Figure 3 Linearity proﬁle of Emtricitabine, Tenofovir and Efavirenz.
Table 4 Assay of Emtricitabine, Tenofovir and Efavirenz in the ﬁxed dose combination tablets.
Sample Batch Content (%) + S.D.
Emtricitabine Tenofovir Efavirenz
Viraday (Cipla) A 100.03 ± 0.42 101.65 ± 0.44 100.01 ± 0.21
B 101.53 ± 0.51 99.27 ± 0.32 101.09 ± 0.27
C 100.31 ± 0.32 99.59 ± 0.37 101.48 ± 0.32
S.D = Standard Deviation; (n = 6).
Table 5 Precision studies for Emtricitabine, Tenofovir and Efavirenz.
Compound % Assay (Day-1,
Analyst-1, Instrument-1)
% RSD of
Assay (N= 6)
% Assay (Day-2, Analyst-2,
Instrument-2)
% RSD of
Assay (N= 6)
Emtricitabine 100.52 0.76 99.31 0.77
Tenofovir 101.07 1.06 100.64 1.01
Efavirenz 99.39 0.68 99.09 0.73
Table 6 Recovery studies for Emtricitabine, Tenofovir and Efavirenz by standard added commercial formulations.
Drug Levels (%) Amount recovered (mg) % Recovery Mean % recovery % RSD
Emtricitabine 80 364.06 100.26 100.09 0.55
100 402.64 099.68 0.48
120 444.17 100.34 0.31
Tenofovir 80 542.85 099.97 099.88 0.45
100 603.03 099.82 0.48
120 661.71 099.84 0.63
Efavirenz 80 1088.66 100.02 100.04 0.21
100 1206.13 100.09 0.27
120 1328.31 100.02 0.18
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Table 7 Robustness studies for Emtricitabine, Tenofovir and Efavirenz.
S.No Condition % RSD
Emtricitabine Tenofovir Efavirenz
1 Flow (+10%) 0.37 0.28 0.52
2 Flow (10%) 0.31 0.18 0.24
3 Temperature (23 C) 0.3 0.21 0.44
4 Temperature (27 C) 0.41 0.43 0.32
5 Wave length (+2 nm) 0.29 0.67 0.28
6 Wave length (2 nm) 0.42 0.21 0.18
7 pH of buﬀer (2.8) 1.02 0.81 0.25
8 pH of buﬀer (3.2) 0.64 0.2 0.23
9 Organic (+2%) 0.18 0.27 0.09
10 Organic (2%) 0.24 0.2 0.12
6 A. Ramaswamy, A.S. Arul Gnana Dhaswith the mixture of the capsule excipients showed no interfer-
ing peaks in the same retention time of Emtricitabine, Tenofo-
vir and Efavirenz.
3.1.6. Robustness
Statistical analysis showed no signiﬁcant difference between
results obtained employing the analytical conditions estab-
lished for the method and those obtained in the experiments
in which variations of some parameters were introduced. Thus,
the method showed to be robust for changes in mobile phase
ﬂow rate 1.35 and 1.65 ml/min, methanol: buffer proportion
(±2% of organic solvent), mobile phase pH (4.3 and 4.7).
The results obtained are presented in Table 7.
3.1.7. Detection and quantitation limits
According to the determined signal-to-noise ratio, Emtricita-
bine, Tenofovir, and Efavirenz presented limits of detection
of 0.38, 0.76, 0.94 lg/ml and limits of quantitation of 1.25,
2.5, 3.10 lg/ml, respectively where the compound proportion
was found in the sample solutions injected onto the chromato-
graph. However, the objective of the method is the quantita-
tion of Emtricitabine, Tenofovir, and Efavirenz, so the
values obtained for Emtricitabine, Tenofovir, and Efavirenz
should be considered as the limit of method sensitivity.
The development of a simple and reliable method is essen-
tial to assure the identiﬁcation and quantitative determination
of antiretroviral drugs since the problem of counterfeit or
substandard antiretrovirals is well established all over the
world. The quality control of the antiretroviral pharmaceutical
preparations marketed nowadays may help to assure the
treatment efﬁcacy and avoid the development of resistance to
antiretrovirals drugs.
4. Conclusion
This study was the ﬁrst report of development and validation
of Emtricitabine, Tenofovir, and Efavirenz in pure form for
pharmaceutical formulations. The developed method showed
to be a simple, precise, accurate and suitable technique to
quantify the antiretrovirals and might be employed for quality
control analysis as well as in further studies in other matrices,
such as plasma. Emtricitabine, Tenofovir, and Efavirenz
tablets analyzed by the validated method showed adequate
quality and drug contents in concordance with the labeled
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